In Vitro and In Silico Analysis of New n-Butyl and Isobutyl Quinoxaline-7-carboxylate 1,4-di- N-oxide Derivatives against Trypanosoma cruzi as Trypanothione Reductase Inhibitors

Int J Mol Sci. 2022 Nov 1;23(21):13315. doi: 10.3390/ijms232113315.

Abstract

American trypanosomiasis is a worldwide health problem that requires attention due to ineffective treatment options. We evaluated n-butyl and isobutyl quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives against trypomastigotes of the Trypanosoma cruzi strains NINOA and INC-5. An in silico analysis of the interactions of 1,4-di-N-oxide on the active site of trypanothione reductase (TR) and an enzyme inhibition study was carried out. The n-butyl series compound identified as T-150 had the best trypanocidal activity against T. cruzi trypomastigotes, with a 13% TR inhibition at 44 μM. The derivative T-147 behaved as a mixed inhibitor with Ki and Ki' inhibition constants of 11.4 and 60.8 µM, respectively. This finding is comparable to the TR inhibitor mepacrine (Ki = 19 µM).

Keywords: Chagas disease; chemical synthesis; quinoxaline-1,4-di-N-oxide; trypanothione reductase; trypomastigotes.

MeSH terms

  • Chagas Disease* / drug therapy
  • Enzyme Inhibitors / chemistry
  • Humans
  • NADH, NADPH Oxidoreductases
  • Oxides / pharmacology
  • Quinoxalines / chemistry
  • Trypanocidal Agents* / chemistry
  • Trypanocidal Agents* / pharmacology
  • Trypanosoma cruzi*

Substances

  • trypanothione reductase
  • Trypanocidal Agents
  • Quinoxalines
  • Oxides
  • quinoxaline-2-carboxamide-1,4-di-N-oxide
  • NADH, NADPH Oxidoreductases
  • Enzyme Inhibitors